Patents by Inventor Andrew Neil Charles Weir
Andrew Neil Charles Weir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7977464Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.Type: GrantFiled: June 18, 2008Date of Patent: July 12, 2011Assignee: UCB Pharma S.A.Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Patent number: 7718157Abstract: Targeted lipids and lipid particles are described which are assemblies of multipolar lipids, targeting molecules such as antibodies and polyanions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.Type: GrantFiled: August 16, 2000Date of Patent: May 18, 2010Inventors: Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall, Michael Anthony William Eaton, Timothy John Norman, David Parker
-
Patent number: 7531676Abstract: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.Type: GrantFiled: July 26, 2005Date of Patent: May 12, 2009Assignee: Celltech R & D LimitedInventors: Michael Anthony William Eaton, Timothy John Norman, David Parker, Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall
-
Publication number: 20080269465Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.Type: ApplicationFiled: June 18, 2008Publication date: October 30, 2008Applicant: UCB PHARMA S.A.Inventors: DILJEET SINGH ATHWAL, DEREK THOMAS BROWN, ANDREW NEIL CHARLES WEIR, ANDREW GEORGE POPPLEWELL, ANDREW PAUL CHAPMAN, DAVID JOHN KING
-
Patent number: 7402662Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.Type: GrantFiled: March 13, 2006Date of Patent: July 22, 2008Assignee: UCB Pharma S.A.Inventors: Dilijeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Patent number: 7186820Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.Type: GrantFiled: September 10, 2001Date of Patent: March 6, 2007Assignee: UCB CelltechInventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Patent number: 7012135Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.Type: GrantFiled: June 6, 2001Date of Patent: March 14, 2006Assignee: Celltech Chiroscience LimitedInventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Publication number: 20040024220Abstract: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.Type: ApplicationFiled: May 9, 2003Publication date: February 5, 2004Applicant: CELLTECH R & D LIMITEDInventors: Michael Anthony William Eaton, Timothy John Norman, David Parker, Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall
-
Patent number: 6583301Abstract: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.Type: GrantFiled: November 20, 2000Date of Patent: June 24, 2003Assignee: Celltech R & D LimitedInventors: Michael Anthony William Eaton, Timothy John Norman, David Parker, Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall
-
Publication number: 20030077249Abstract: A cell activation process is described in which an effector cell is transformed with DNA coding for a chimeric receptor containing two or more different cytoplasmic signalling components.Type: ApplicationFiled: May 17, 1999Publication date: April 24, 2003Inventors: CHRISTOPHER ROBERT BEBBINGTON, ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW NEIL, CHARLES WEIR, HELENE MARGARET FINNEY
-
Publication number: 20030060444Abstract: A cell activation process is described in which an effector cell is transformed with DNA coding for a chimeric receptor containing two or more different cytoplasmic signalling components. At least one of the cytoplasmic signalling components is derived from all or part of a tetraspan-transmembrane protein, CD43, CD6, a mannose, U17, IL-12 or complement receptor, an integrin-associated protein, or a &ggr;-chain associated with a cytokine receptor. The activated cell may be of use in medicine for example in the treatment of diseases such as cancer.Type: ApplicationFiled: October 24, 2002Publication date: March 27, 2003Applicant: CELLTECH THERAPEUTICS, LTD.Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Andrew Neil Charles Weir
-
Publication number: 20030026805Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.Type: ApplicationFiled: October 18, 2001Publication date: February 6, 2003Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Publication number: 20020151682Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.Type: ApplicationFiled: September 10, 2001Publication date: October 17, 2002Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Patent number: 6284488Abstract: A method for expressing recombinant molecules in bacterial hosts in a defined medium in the absence of antibiotic selection is disclosed. The method uses an expression vector comprising a regulatable promoter by which the production of foreign proteins may be controlled during the growth phase of the culture, and origin of replication maintaining medium vector copy number and a transcriptional promoter.Type: GrantFiled: June 18, 1999Date of Patent: September 4, 2001Assignee: Celltech Therapeutics LimitedInventors: Andrew Neil Charles Weir, Andrew Mountain
-
Patent number: 5928903Abstract: The invention provides a method for the expression of recombinant molecules in bacterial hosts in a defined medium in the absence of antibiotic selection. The method uses an expression vector comprising a regulatable promoter by which the production of foreign proteins may be controlled during the growth phase of the culture, an origin of replication maintaining medium vector copy number and a transcriptional terminator.Type: GrantFiled: March 14, 1995Date of Patent: July 27, 1999Assignee: Celltech Therapeutics LimitedInventors: Andrew Neil Charles Weir, Andrew Mountain
-
Patent number: 5665866Abstract: This invention relates to a process for obtaining antibodies in soluble and correctly folded and assembled form. It comprises a step to raise the temperature at a time in the process selected to facilitate the subsequent isolation of soluble, correctly folded and assembled antibody, substantially free of other antibody-related material. The operating temperature may be raised at any stage in the microbial fermentation or eukaryotic cell culture, or at any stage during extraction and purification of the antibodies.Type: GrantFiled: March 14, 1995Date of Patent: September 9, 1997Assignee: Celltech Therapeutics LimitedInventors: Andrew Neil Charles Weir, Neil Andrew Bailey